CA2497575A1 - Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire - Google Patents

Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire Download PDF

Info

Publication number: CA2497575A1
Authority: CA; Canada
Prior art keywords: tissue; spectrum; light; radiation; frequency
Prior art date: 1991-02-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002497575A

Other languages

English (en)

Inventor

Michael S. Feld

Richard P. Rava

Joseph J. Baraga

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Massachusetts Institute of Technology

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-26

Filing date

1992-01-17

Publication date

1992-09-03

1992-01-17 Application filed by Individual filed Critical Individual

1992-01-17 Priority claimed from CA002104960A external-priority patent/CA2104960C/fr

1992-09-03 Publication of CA2497575A1 publication Critical patent/CA2497575A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 105
238000003745 diagnosis Methods 0.000 title claims abstract description 41
238000010905 molecular spectroscopy Methods 0.000 title abstract description 4
238000001069 Raman spectroscopy Methods 0.000 claims abstract description 54
230000005855 radiation Effects 0.000 claims abstract description 37
238000001228 spectrum Methods 0.000 claims description 208
230000003595 spectral effect Effects 0.000 claims description 33
239000000835 fiber Substances 0.000 claims description 28
210000001367 artery Anatomy 0.000 claims description 27
230000001678 irradiating effect Effects 0.000 claims description 18
230000003287 optical effect Effects 0.000 claims description 18
238000004611 spectroscopical analysis Methods 0.000 claims description 14
230000004044 response Effects 0.000 claims description 10
238000002329 infrared spectrum Methods 0.000 claims description 8
230000002596 correlated effect Effects 0.000 claims description 4
238000003780 insertion Methods 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
230000008878 coupling Effects 0.000 claims 3
238000010168 coupling process Methods 0.000 claims 3
238000005859 coupling reaction Methods 0.000 claims 3
238000005102 attenuated total reflection Methods 0.000 abstract description 86
238000005259 measurement Methods 0.000 abstract description 17
239000000203 mixture Substances 0.000 abstract description 17
238000011282 treatment Methods 0.000 abstract description 9
230000001575 pathological effect Effects 0.000 abstract description 3
210000001519 tissue Anatomy 0.000 description 163
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 76
239000000523 sample Substances 0.000 description 68
150000002632 lipids Chemical class 0.000 description 59
210000000709 aorta Anatomy 0.000 description 57
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
235000012000 cholesterol Nutrition 0.000 description 42
150000001408 amides Chemical class 0.000 description 39
102000004169 proteins and genes Human genes 0.000 description 39
108090000623 proteins and genes Proteins 0.000 description 39
235000018102 proteins Nutrition 0.000 description 37
230000001338 necrotic effect Effects 0.000 description 30
208000037260 Atherosclerotic Plaque Diseases 0.000 description 29
230000005284 excitation Effects 0.000 description 29
230000009102 absorption Effects 0.000 description 28
238000010521 absorption reaction Methods 0.000 description 28
238000005079 FT-Raman Methods 0.000 description 25
238000001237 Raman spectrum Methods 0.000 description 21
238000005452 bending Methods 0.000 description 21
239000013307 optical fiber Substances 0.000 description 21
239000000463 material Substances 0.000 description 19
230000003143 atherosclerotic effect Effects 0.000 description 18
238000005070 sampling Methods 0.000 description 15
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
239000010410 layer Substances 0.000 description 14
208000004434 Calcinosis Diseases 0.000 description 11
102000008186 Collagen Human genes 0.000 description 11
108010035532 Collagen Proteins 0.000 description 11
102000016942 Elastin Human genes 0.000 description 11
108010014258 Elastin Proteins 0.000 description 11
229910019142 PO4 Inorganic materials 0.000 description 11
230000002308 calcification Effects 0.000 description 11
229920001436 collagen Polymers 0.000 description 11
229920002549 elastin Polymers 0.000 description 11
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 11
239000010452 phosphate Substances 0.000 description 11
230000003902 lesion Effects 0.000 description 10
230000035515 penetration Effects 0.000 description 10
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
210000000577 adipose tissue Anatomy 0.000 description 8
150000004665 fatty acids Chemical class 0.000 description 8
201000001320 Atherosclerosis Diseases 0.000 description 7
238000001514 detection method Methods 0.000 description 7
239000007787 solid Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
229910000530 Gallium indium arsenide Inorganic materials 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
210000002808 connective tissue Anatomy 0.000 description 5
239000000470 constituent Substances 0.000 description 5
239000013078 crystal Substances 0.000 description 5
238000003384 imaging method Methods 0.000 description 5
238000004476 mid-IR spectroscopy Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
150000001841 cholesterols Chemical class 0.000 description 4
238000010586 diagram Methods 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
238000002095 near-infrared Raman spectroscopy Methods 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
230000007170 pathology Effects 0.000 description 4
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
230000008569 process Effects 0.000 description 4
SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 3
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
239000007975 buffered saline Substances 0.000 description 3
235000021466 carotenoid Nutrition 0.000 description 3
150000001747 carotenoids Chemical class 0.000 description 3
230000008859 change Effects 0.000 description 3
150000001840 cholesterol esters Chemical class 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000001066 destructive effect Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
238000005286 illumination Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
238000011886 postmortem examination Methods 0.000 description 3
239000010453 quartz Substances 0.000 description 3
210000004872 soft tissue Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 3
229940117972 triolein Drugs 0.000 description 3
230000036269 ulceration Effects 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
238000004566 IR spectroscopy Methods 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
206010035148 Plague Diseases 0.000 description 2
241000607479 Yersinia pestis Species 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000005253 cladding Methods 0.000 description 2
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000002189 fluorescence spectrum Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000007689 inspection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
239000011435 rock Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000012306 spectroscopic technique Methods 0.000 description 2
125000002328 sterol group Chemical group 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
-1 triglyceride ester Chemical class 0.000 description 2
125000005314 unsaturated fatty acid group Chemical group 0.000 description 2
GTRMJEVFVTWDIU-KPNWGBFJSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;hydrate Chemical compound O.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GTRMJEVFVTWDIU-KPNWGBFJSA-N 0.000 description 1
CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
210000001361 achilles tendon Anatomy 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
238000002583 angiography Methods 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000005068 bladder tissue Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000000205 computational method Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
238000012937 correction Methods 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000000295 emission spectrum Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000002795 fluorescence method Methods 0.000 description 1
238000001506 fluorescence spectroscopy Methods 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
IBDXZWQCLMSDKQ-FDXOKOSPSA-N i-cholesterol Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)[C@H](C)CCCC(C)C)[C@@H](O)[C@@]31[C@H]2C3 IBDXZWQCLMSDKQ-FDXOKOSPSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000013152 interventional procedure Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000000608 laser ablation Methods 0.000 description 1
238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
239000002352 surface water Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000000411 transmission spectrum Methods 0.000 description 1
125000005457 triglyceride group Chemical group 0.000 description 1
238000002460 vibrational spectroscopy Methods 0.000 description 1
238000001845 vibrational spectrum Methods 0.000 description 1

Landscapes

Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

CA002497575A 1991-02-26 1992-01-17 Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire Abandoned CA2497575A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US66107791A	1991-02-26	1991-02-26
US661,077		1991-02-26
CA002104960A CA2104960C (fr)	1991-02-26	1992-01-17	Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002104960A Division CA2104960C (fr)	1991-02-26	1992-01-17	Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire

Publications (1)

Publication Number	Publication Date
CA2497575A1 true CA2497575A1 (fr)	1992-09-03

Family

ID=34423898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002497575A Abandoned CA2497575A1 (fr)	1991-02-26	1992-01-17	Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire

Country Status (1)

Country	Link
CA (1)	CA2497575A1 (fr)

1992
- 1992-01-17 CA CA002497575A patent/CA2497575A1/fr not_active Abandoned

Publication	Publication Date	Title
EP0573535B1 (fr)	2000-12-27	Systemes et procedes de spectroscopie moleculaire, permettant d'etablir le diagnostic des tissus
US6091984A (en)	2000-07-18	Measuring tissue morphology
US6208887B1 (en)	2001-03-27	Catheter-delivered low resolution Raman scattering analyzing system for detecting lesions
US5042494A (en)	1991-08-27	Method and apparatus for detecting cancerous tissue using luminescence excitation spectra
JP4474050B2 (ja)	2010-06-02	マルチモード光学組織診断システム
US20020156380A1 (en)	2002-10-24	Raman endoscope
CA2658811C (fr)	2014-03-18	Spectroscopie multimodale
US20090326385A1 (en)	2009-12-31	Obtaining optical tissue properties
US7508524B2 (en)	2009-03-24	Combined raman spectroscopy-optical coherence tomography (RS-OCT) system and applications of the same
US9788728B2 (en)	2017-10-17	Endoscopic polarized multispectral light scattering scanning method
US20050203419A1 (en)	2005-09-15	Side-firing probe for performing optical spectroscopy during core needle biopsy
EP2327978A2 (fr)	2011-06-01	Systèmes et procédés pour spectroscopie d'un tissu biologique
US20170202462A1 (en)	2017-07-20	Systems and methods for spectroscopy of biological tissue
JP2006508358A (ja)	2006-03-09	組織を測定するための高波数ラマン分光法の使用
CN101115986A (zh)	2008-01-30	对次表面组织和液体的拉曼光谱分析
Hoyt et al.	1988	Remote biomedical spectroscopic imaging of human artery wall
JP2007524833A (ja)	2007-08-30	骨組織の状態を診断するための方法および装置
US20100317974A1 (en)	2010-12-16	Detection of vulnerable plaques by raman spectroscopy
EP1704814B1 (fr)	2008-10-29	Appareil pour la tomographie optique
CA2497575A1 (fr)	1992-09-03	Systemes et methodes de spectroscopie moleculaire pour diagnostic tissulaire
Fitzmaurice et al.	2005	Raman spectroscopy: development of clinical applications for breast cancer diagnosis
RU2152162C1 (ru)	2000-07-10	Способ повышения точности обнаружения злокачественных новообразований и определения границ их локализации
AU781659B2 (en)	2005-06-02	Method for measuring tissue morphology
JPS58118948A (ja)	1983-07-15	分光分析による異常細胞の検出方法及び装置

Legal Events

Date	Code	Title	Description
2005-03-07	EEER	Examination request
2007-01-17	FZDE	Dead